In the Ever-Evolving World of Infectious Disease, the Bottom Line Is Evidence Matters
Editor-in-chief, Jason C. Gallagher, PharmD, FCCP, FIDSA, BCPS, shares how it is up to all of us in health care to evaluate the level of evidence in our practices and continue to evolve, just like the organisms we work to treat.
Intravenous Fosfomycin In Development for United States
Because of the recent concern in the United States around the rise of resistant pathogens, intravenous fosfomycin has gained renewed interest because of its activity and demonstrated synergy with other classes of antibiotics.
Pheno Bacterial Identification and Antimicrobial Susceptibility Determination Found to Be More Rapid and as Accurate as Existing Systems
The system allows for the rapid identification of bacteria directly from positive blood cultures, and can determine the antimicrobial susceptibility of the blood-borne pathogens.
Accelerate Pheno Blood Culture Detection System Found to Shorten Blood Analysis Time
Use of the FDA–cleared Accelerate Pheno blood culture detection system can shorten the time required to analyze patients’ blood samples leading to improved clinical outcomes, according to the results of a recent study.
Multidrug-Resistant Infections: Implementing Programs for Antimicrobial Stewardship
Key considerations when choosing a treatment for gram-negative nosocomial infections include the patient’s referring facility.
US Health Care-Associated Infection Progress Report Shows Some Improvement
A new report from the CDC shows substantial progress on the incidence of health care-associated infections in the United States, but there is still more work to be done.
Top Infectious Disease News of the Week—October 14, 2018
Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.
Hospital-Acquired and Ventilator-Associated Pneumonia: Highlights and Pitfalls of the 2016 IDSA / ATS Guidelines
Hospital-acquired and ventilator-associated pneumonia account for 22% of all hospital-acquired infections.
New Technologies To Fight Pandemics—From Prevention to Response
A new report highlights technologies with potential to prevent and reduce global catastrophic biological risks.
Common Probiotic Appears to Eliminate S aureus Colonies
Probiotic Bacillus found to eliminate colonies of S aureus in mouse models and was associated with a lack of S aureus in human samples.
Plazomicin: A Novel Aminoglycoside
The drug presents a new option for patients at high risk of infections caused by organisms, such as carbapenem-resistant Enterobacteriaceae.
Comparison of Ceftolozane/Tazobactam vs Polymyxin/Amingoglycoside for Treatment of MDR/XDR Pseudomonas aeruginosa
Jason Pogue, PharmD, BCPS-AQID, discusses the need for real-world data to support Ceftolozane/tazobactam and shares the findings of his comparative study on using the regimen to treat MDR/XDR Pseudomonas aeruginosa.
Dr. George Thompson On Phase 2 STRIVE Study Evaluating Optimal Dosing for Rezafungin
George Thompson, MD, principal investigator of the STRIVE study discusses optimal dosing for rezafungin in treating candidemia and/or invasive candidiasis.
New Options on the Horizon for C diff Prevention
Dale N Gerding, MD, provides insight about prevention options for C diff that are expected in the future.
Saline Nasal Irrigations and Bacterial Contamination
Contamination is a common aspect of nasal saline irrigations.
Evaluation of Fidaxomicin vs Vancomycin in Early Targeted Therapy of C diff
Nimish Patel, PharmD, PhD, describes his study, which compared fidaxomicin with oral vancomycin in early targeted therapy of C diff.
Rapid Molecular Tests Can Aid Empiric Therapy Decisions in P aeruginosa Cases
Scientists sought to figure out whether rapid diagnostic tests could be used to determine the susceptibility of P aeruginosa to 2 new therapies. The answer was yes, but with caveats.
Paradigm Shift in Treatment for ABSSSI
Yoav Golan, MD, discusses the paradigm shift occurring in treatment for ABSSSI and how to motivate clinicians to buy into new programs and protocols.
A Deadly Duo: MCR-1 Genes and Duodenoscopes
Duodenoscopes are at fault for another infectious disease outbreak, and this time it's with a highly-resistant bacteria.
FDA Announces New Plan to Fight Antimicrobial Resistance
The program calls for new research and development incentives, veterinary stewardship, and enhanced surveillance.
The Dangers of Overtreating Asymptomatic Bacteriuria
Barbara Wells Trautner, MD, PhD, explains how overtreating asymptomatic bacteriuria can lead to antibiotic resistance or incorrect diagnoses.
Ceftolozane & Tazobactam Proves Noninferior to Meropenem in Patients with HABP or VABP
Ceftolozane and tazobactam proves noninferior to meropenem in a pivotal phase 3 trial of adult patients with HABP or VABP.
The Rise of Resistant Staphylococcus epidermidis
Common skin bacteria have gained resistance to multiple antibiotics.
Research Reveals Potential New Marker for Mortality Due to Clostridium difficile Infection
A new study is the first to identify eosinophil counts as a predictor of outcomes in human patients.
Are Rapid Diagnostics Replacing Prediction Scores?
Julie Ann Justo, PharmD, MS, BCPS-AQ ID, explains how rapid diagnostics interplay with prediction scores in antimicrobial stewardship programs.
Top Infectious Disease News of the Week—September 2, 2018
Telavancin Promising Potential Treatment Option for MRSA in Cystic Fibrosis Patients
Investigators find telavancin has potent in vitro activity and low resistance development potential when used against S aureus isolates in patients with cystic fibrosis.
Use of Oritavancin as Outpatient Treatment for ABSSTIs Generates Potential Cost Savings at Community Hospital
Additional evidence supports the use of oritavancin as a cost-saving outpatient treatment for acute bacterial skin and skin structure infections (ABSSTIs) in patients who would otherwise be admitted to the hospital for therapy.
Going Against the Norm: Testing A New Skin Disinfectant
Can we find an alternative for chlorhexidine gluconate?
Top Infectious Disease News of the Week—August 19, 2018
2 Clarke Drive Cranbury, NJ 08512